Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Acorda Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Acorda Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Acorda Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Acorda Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Acorda Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Acorda Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Acorda Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Acorda Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Acorda Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Acorda Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Acorda Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Acorda Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Acorda Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Acorda Therapeutics, Inc. Snapshot 5 Acorda Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Acorda Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Acorda Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Acorda Therapeutics, Inc. - Pipeline Products Glance 13 Acorda Therapeutics, Inc. - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Acorda Therapeutics, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Acorda Therapeutics, Inc. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Acorda Therapeutics, Inc. - Drug Profiles 18 diazepam 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 capsaicin 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 dalfampridine ER 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 AC-105 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 NP-1998 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 cimaglermin alfa 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 rHIgM-22 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Enzyme To Inhibit Chondroitin Sulfate Proteoglycan For Spinal Cord Injury And Brain Injury 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Tenascin-C Fragments For Spinal Cord Injury 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Acorda Therapeutics, Inc. - Pipeline Analysis 33 Acorda Therapeutics, Inc. - Pipeline Products by Target 33 Acorda Therapeutics, Inc. - Pipeline Products by Route of Administration 35 Acorda Therapeutics, Inc. - Pipeline Products by Molecule Type 36 Acorda Therapeutics, Inc. - Pipeline Products by Mechanism of Action 37 Acorda Therapeutics, Inc. - Recent Pipeline Updates 39 Acorda Therapeutics, Inc. - Dormant Projects 48 Acorda Therapeutics, Inc. - Company Statement 49 Acorda Therapeutics, Inc. - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 58 Disclaimer 58
List of Tables Acorda Therapeutics, Inc., Key Information 5 Acorda Therapeutics, Inc., Key Facts 5 Acorda Therapeutics, Inc. - Pipeline by Indication, 2014 7 Acorda Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 Acorda Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 Acorda Therapeutics, Inc. - Partnered Products in Pipeline, 2014 11 Acorda Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Acorda Therapeutics, Inc. - Pre-Registration, 2014 13 Acorda Therapeutics, Inc. - Phase III, 2014 14 Acorda Therapeutics, Inc. - Phase II, 2014 15 Acorda Therapeutics, Inc. - Phase I, 2014 16 Acorda Therapeutics, Inc. - Preclinical, 2014 17 Acorda Therapeutics, Inc. - Pipeline by Target, 2014 34 Acorda Therapeutics, Inc. - Pipeline by Route of Administration, 2014 35 Acorda Therapeutics, Inc. - Pipeline by Molecule Type, 2014 36 Acorda Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 38 Acorda Therapeutics, Inc. - Recent Pipeline Updates, 2014 39 Acorda Therapeutics, Inc. - Dormant Developmental Projects,2014 48 Acorda Therapeutics, Inc., Subsidiaries 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.